AIM vs ALDX

AIM ImmunoTech Inc. vs Aldeyra Therapeutics, Inc. — Valuation Comparison 2026

AIM

Biotechnology
AIM ImmunoTech Inc.
Quality
4.2
out of 10
Value Trap
32
LOW
Price
$0.44
Last close
Models
8/13
Active
VS

ALDX

Biotechnology
Aldeyra Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
30
LOW
Price
$1.75
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType AIM Fair ValueAIM Upside ALDX Fair ValueALDX Upside
Bayesian DCF Intrinsic $0.14 -66.9% $0.96 -45.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.02 -95.5% $0.07 -95.3%
Dynamic NAV Asset-Based $1.51 +245.6% $1.76 +0.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AIM vs ALDX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AIM vs ALDX — Which Stock Is More Undervalued?

ALDX scores higher with a 4.5/10 quality rating vs AIM's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AIM ImmunoTech Inc. (AIM) and Aldeyra Therapeutics, Inc. (ALDX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AIM currently trades at $0.44 with a QOC of 4.2/10, while ALDX trades at $1.75 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).